Pfizer Exubera review
Executive Summary
Pfizer's inhaled insulin product Exubera will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on Sept. 8. The committee will evaluate the NDA (21-868) for 1 mg and 3 mg doses of the recombinant insulin inhalation powder for treatment of diabetes mellitus in adults. The meeting will be held at the Holiday Inn in Silver Spring, Md. beginning at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]....
|
Pfizer's inhaled insulin product Exubera will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on Sept. 8. The committee will evaluate the NDA (21-868) for 1 mg and 3 mg doses of the recombinant insulin inhalation powder for treatment of diabetes mellitus in adults. The meeting will be held at the Holiday Inn in Silver Spring, Md. beginning at 8 a.m. [Editor's Note: To 1 watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.] ..... |